Compare ING Groep NV (ING) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Sanofi SA — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: ING Groep NV and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Sanofi SA for 94 Days on average.
| ING | SNY | |
|---|---|---|
Market Cap | $93.76B | $95.18B |
Volume | 4,620,220 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $37.27 | $52.34 |
52-Week Low | $23.66 | $39.51 |
Typical Hold Time | 94 Days | 94 Days |
Enterprise Value | $236.48B | $114.48B |
Dividend Yield | 3.95% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.37, down 1.62% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue for 2025 reached $22.90 billion, with a net income margin of 28.34%, though cash flow trends show persistent net outflows. Analyst consensus is bullish with 11 buy ratings and no sell recommendations.
The outlook for ING is supported by raised ROE targets and organic growth initiatives, but risks include negative cash flows and regulatory scrutiny. The stock offers value with a P/E of 12.86 and dividend yield, yet investors face headwinds from operational cash burn and macroeconomic sensitivity.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
